Elanco Animal Health (ELAN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.34
- EPS estimate
- $0.27
- EPS surprise
- +26.30%
- Revenue surprise
- +4.23%
- Revenue
- $1.4B
- Revenue estimate
- $1.3B
- Reported
- Aug 5, 2026
Elanco reported Q2 2026 results on August 5, 2026. Earnings per share came in at $0.34, ahead of the $0.27 estimate by 26.30%. Revenue was $1.4 billion against a $1.3 billion consensus, a 4.23% revenue surprise. Compared with Q2 2025, EPS rose about 31% from $0.26 and revenue rose from $1.2 billion.
Annual EPS in the table was $1.11 in 2022, $0.89 in 2023, $0.91 in 2024 and $0.95 in 2025. The first half of 2026 adds up to $0.74, about 17.5% more than the $0.63 of the first half of 2025. Quarterly revenue stayed between about $1.0 billion and $1.2 billion through 2025, then reached $1.4 billion in both 2026 quarters. Second-half EPS trailed the first half in every full year shown. The quarterly high in the table is $0.45 in Q1 2023 and the low is $0.08 in Q4 2023. Elanco beat the EPS estimate in 18 of the last 20 quarters; the misses were Q4 2023 and Q4 2024.
Elanco reported its Q3 results between November 5 and November 8 in each year from 2021 to 2025. That points to early November 2026 for the next report, which will compare with Q3 2025 EPS of $0.19.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.27 | $0.34 | +26.30% | $1.4B | SEC |
| Q1 2026 | May 6, 2026 | $0.35 | $0.40 | +15.74% | $1.4B | SEC |
| Q4 2025 | Feb 24, 2026 | $0.11 | $0.13 | +14.54% | $1.1B | SEC |
| Q3 2025 | Nov 5, 2025 | $0.13 | $0.19 | +46.15% | $1.1B | SEC |
| Q2 2025 | Aug 7, 2025 | $0.20 | $0.26 | +30.85% | $1.2B | SEC |
| Q1 2025 | May 7, 2025 | $0.31 | $0.37 | +20.80% | $1.2B | SEC |
| Q4 2024 | Feb 25, 2025 | $0.15 | $0.14 | −6.04% | $1.0B | SEC |
| Q3 2024 | Nov 7, 2024 | $0.12 | $0.13 | +6.21% | $1.0B | SEC |
| Q2 2024 | Aug 8, 2024 | $0.24 | $0.30 | +25.16% | $1.2B | SEC |
| Q1 2024 | May 8, 2024 | $0.27 | $0.34 | +24.09% | $1.2B | SEC |
| Q4 2023 | Feb 26, 2024 | $0.10 | $0.08 | −23.44% | $1.0B | SEC |
| Q3 2023 | Nov 7, 2023 | $0.12 | $0.18 | +44.46% | $1.1B | SEC |
| Q2 2023 | Aug 7, 2023 | $0.05 | $0.18 | +282.17% | $1.1B | SEC |
| Q1 2023 | May 9, 2023 | $0.29 | $0.45 | +57.89% | $1.3B | SEC |
| Q4 2022 | Feb 21, 2023 | $0.13 | $0.19 | +49.14% | $988.0M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.16 | $0.20 | +26.10% | $1.0B | — |
| Q2 2022 | Aug 8, 2022 | $0.25 | $0.36 | +42.74% | $1.2B | — |
| Q1 2022 | May 9, 2022 | $0.35 | $0.36 | +1.93% | $1.2B | — |
| Q4 2021 | Feb 24, 2022 | $0.17 | $0.20 | +18.76% | $1.1B | — |
| Q3 2021 | Nov 5, 2021 | $0.17 | $0.19 | +14.94% | $1.1B | — |
Quarterly revenue
Frequently asked questions
When did Elanco Animal Health (ELAN) last report earnings?
Elanco Animal Health last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did ELAN beat earnings estimates?
Yes. Elanco Animal Health reported EPS of $0.34 for Q2 2026 against a $0.27 estimate — a 26.30% beat.
How much revenue did ELAN report last quarter?
Elanco Animal Health reported $1.4B in revenue for Q2 2026, against a consensus estimate of $1.3B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.